Hyundai Pharmaceutical Co., Ltd.(KR:004310)
₩6,690.00+70.00 (+1.06%)
KR:004310
Hyundai Pharmaceutical Co., Ltd. financials statements
₩6,690.00
At close:+70.00 (+1.06%)
Want to see KR:004310 full AI Analyst Report?
Hyundai Pharmaceutical Co., Ltd. (004310) Income Statement
Hyundai Pharmaceutical Co., Ltd. Income Statement
Last quarter (Q3 2026), Hyundai Pharmaceutical Co., Ltd.'s total revenue was ₩56.27B, an increase of 9.13% from the same quarter last year. In Q3, Hyundai Pharmaceutical Co., Ltd.'s net income was ₩1.71B. See Hyundai Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Nov 25 | Nov 24 | Nov 23 | Nov 22 | Nov 21 |
|---|---|---|---|---|---|
| ₩ 191.79B | ₩ 175.74B | ₩ 180.76B | ₩ 162.69B | ₩ 139.80B | |
| ₩ 78.23B | ₩ 73.37B | ₩ 75.24B | ₩ 68.84B | ₩ 56.31B | |
| ₩ 74.93B | ₩ 73.18B | ₩ 68.31B | ₩ 60.87B | ₩ 57.88B | |
| Depreciation and Amortization | ₩ 4.28B | ₩ 3.69B | ₩ 3.30B | ₩ 3.30B | ₩ 3.98B |
| ₩ 7.58B | ₩ 3.94B | ₩ 13.21B | ₩ 10.04B | ₩ 670.96M | |
| ₩ 3.30B | ₩ 180.89M | ₩ 6.93B | ₩ 7.97B | ₩ -1.57B | |
| ₩ -992.51M | ₩ -1.91B | ₩ 1.11B | ₩ -2.30B | ₩ -2.45B | |
| ₩ 2.31B | ₩ -1.73B | ₩ 8.03B | ₩ 5.67B | ₩ -4.02B | |
| ₩ 2.52B | ₩ -574.89M | ₩ 6.12B | ₩ -164.58M | ₩ -3.17B | |
| Per Share Metrics | |||||
| Basic EPS | ₩ 96.28 | ₩ -22.41 | ₩ 225.81 | ₩ -5.92 | ₩ -113.82 |
| Diluted EPS | ₩ 96.28 | ₩ -22.41 | ₩ 225.81 | ₩ -5.92 | ₩ -113.82 |
| Weighted Average Shares Outstanding | 26.14M | 25.65M | 27.11M | 27.81M | 27.88M |
| Weighted Average Shares Outstanding (Diluted) | 26.14M | 25.65M | 27.11M | 27.81M | 27.88M |
Currency in KRW
